对初级保健中中年成年人针对性痴呆风险降低干预措施的系统审查
Mary Tullipan1, Johnson George2, Parker Magin3
1Centre for Medicine Use and Safety, Monash University Faculty of Pharmacy and Pharmaceutical Sciences, Parkville, Victoria, Australia.
The journal of prevention of Alzheimer's disease
|May 7, 2025
概括
在中年期的多领域痴呆风险降低干预措施显示出潜力,但需要进一步评估. 目前的证据尚未确定,没有观察到显著的认知变化,尽管一些研究降低了风险得分.
科学领域:
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
- 老年学是一门学科.
背景情况:
- 痴呆症病理始于中年,这使得这个时期对于降低风险至关重要.
- 针对多种风险因素的多领域干预措施正在探索痴呆症预防.
研究的目的:
- 对专门针对中年人群的多领域痴呆风险降低干预措施的文献进行审查.
- 评估该领域现有研究的有效性和质量.
主要方法:
- 在MEDLINE,CINAHL和EMBASE数据库中进行系统搜索.
- 纳入标准:年龄在45-65岁的参与者,初级保健环境,准≥2个痴呆风险因素,并测量认知功能或风险评分.
- 使用修订后的Cochrane偏差风险评估工具进行偏差评估.
主要成果:
- 包括七项研究,参与者的年龄从45.3岁到64.2岁不等.
- 干预的持续时间差异很大 (10周至9.8年),针对2-6个风险因素.
- 没有发现统计学意义上的认知改善;两项研究显示,痴呆症风险得分降低. 在三项研究中发现了偏差的高风险.
结论:
- 关于中年多领域痴呆风险降低的证据是不确定的,但由于潜在的益处和低危害,有希望.
- 需要进一步的研究,进行更长的随访,更广泛的风险因素向和一致的结果措施.
- 临床实践中的实施需要进一步评估,重点是最大限度地提高有效性和长期影响.
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...


